Bone Biologics Corp Completes Financing With HIC

EDISON, N.J., Nov. 3, 2014 /PRNewswire/ -- Bone Biologics, Corp., ("Bone Biologics" or "The Company") announced today the completion of a $5M funding round with Hankey Investment Company, LP ("HIC") of Los Angeles CA. The company is developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or Nell-1) for use with patients undergoing spinal fusion. Forefront Capital acted as placement agent for the transaction.

Michael Schuler, CEO of Bone Biologics noted, "We are pleased with the completion of this round of funding which will now allow the company to begin the process of manufacturing Nell-1 in preparation for human clinical trials to validate the technology in regenerative medicine for bone."

Nell-1, a bone growth factor has been developed by Bone Biologics, Inc. in partnership with University of California, Los Angeles (UCLA) and the Musculoskeletal Transplant Foundation (MTF) as a more specific alternative to other bone growth factors used in health care today. In large animal studies, Nell-1 exhibited none of the side effects currently associated with other bone growth factors including ectopic bone growth, extraneous bone growth or cyst formation. The next phase will be completing the development and testing work needed to seek regulatory approval for the initial pilot study in human clinical trials.

Bone Biologics Board Chairman Bruce Stroever stated, "We are very pleased that funding has been secured to supplement the initial funding provided by MTF. The technology developed by UCLA and Bone Biologics, Inc. has the potential to make a significant difference in patient's lives, dramatically speeding spinal fusion, while controlling healthcare costs." Stroever is the President and CEO of MTF.

Don R. Hankey, Chairman of HIC said, "We are very happy for the opportunity to enable Bone Biologics to progress to the next phase of its business plan and look forward to the future success of its innovative process."

About Bone Biologics

Bone Biologics was founded by University of California Los Angeles professors in collaboration with an Osaka University professor, and a USC surgeon in 2004. Formed to pursue regenerative medicine for bone, the company currently has as its strategic partners the Musculoskeletal Transplant Foundation, the nation's leading tissue bank and Orthofix a leading global medical device company. Bone Biologics is currently focused on bone regeneration in spinal fusion using its recombinant human protein known as Nell-1. Nell-1 is an osteoinductive orthobiologic; a recombinant protein that provides control over bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA.

About MTF

The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987 MTF has received tissue from more than 100,000 donors and distributed more than five million grafts for transplantation. For more information visit www.mtf.org

About HIC

Hankey Investment Company, LP, a member of the Hankey Group of Companies, is a private equity firm based in Los Angeles, California.  With outstanding receivables in excess of $300MM, HIC's primary focus is on asset-based finance solutions.  

Forward-Looking Statements

This press release contains forward-looking statements that reflect the Company's current beliefs, expectations or intentions regarding future events.  Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements.  Words such as "will," "will be,"  "anticipate," "predict," "continue," "future," and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent current report on Form 8-K, filed with the Securities and Exchange Commission on September 25, 2014. The Company anticipates that subsequent events and developments may cause their views and expectations to change. The Company assumes no obligation, and they specifically disclaim any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For Information contact:

William Jay Treat, Ph.D., (732-661-2224) 

SOURCE Bone Biologics, Corp.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED